Denosumab Most Effective in High-Risk Prostate Cancer Patients

The anti-RANKL antibody denosumab is more effective for preventing bone metastasis in men with high-risk castration-resistant prostate cancer compared with low-risk disease, according to results of a new study.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news